Agilent Technologies, Inc.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Padraig Mcdonnell
- Full Time Employees
- 18,100
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- 5301 Stevens Creek Boulevard Santa Clara CA United States 95051
- IPO Date
- Nov 18, 1999
- CIK
- 0001090872
- Website
- agilent.com
- Similar Companies
- Business
- Agilent Technologies, Inc. (NYSE: A) provides instruments, software, services, and consumables for the life sciences, diagnostics, chemical analysis, and applied markets. The company offers a broad portfolio of products and services including gas chromatography and liquid chromatography systems; mass spectrometry and molecular spectroscopy instruments; microarrays, automation, and informatics solutions; bioreagents, FISH probes, target enrichment, and next-generation sequencing tools; immunohistochemistry and pathology solutions; genomics, proteomics, and cell analysis platforms; sample preparation, GC and HPLC columns, spectrometry supplies, and consumables; as well as laboratory management services encompassing enterprise asset management, compliance support, training, and CrossLab virtual assist for remote technical support. Headquartered in Santa Clara, California, Agilent operates globally in more than 100 countries, serving analytical laboratories, pharmaceutical, biopharma, clinical diagnostics, environmental, forensics, food, energy, academia, and government sectors; it was spun off from Hewlett-Packard in 1999. Recent developments include the completion of its $925 million acquisition of BIOVECTRA, Inc., a Canada-based contract development and manufacturing organization specializing in biologics, active pharmaceutical ingredients, sterile fill-finish, plasmid DNA, mRNA, lipid nanoparticles, antibody-drug conjugates, and high-potency APIs, enhancing Agilent's CDMO capabilities for gene editing and therapeutics; a $7 million investment to modernize R&D and applications labs in Delaware; the launch of the Agilent Innovation Hub in partnership with the University of Melbourne; a strategic collaboration with SeqOne for liquid biopsy data analysis in oncology; and expansions such as a $725 million nucleic acid therapeutics facility in Frederick, Colorado, alongside new product launches driving growth in specialty CDMO services for siRNA and GLP-1 modalities.
Company News
Agilent to Announce Fourth-Quarter Fiscal Year 2026 Financial Results on Nov. 23
Parnassus Mid Cap Growth Fund: Q3 2026 Performance Review
Parnassus Mid Cap Fund Q3 2026 Portfolio Review
Carillon Scout Mid Cap Fund Q3 2026 Portfolio Review
Agilent and University of Chicago Launch Center of Excellence for Energy Materials Research
Dividend Champion, Contender, And Challenger Highlights: Week October 25
Agilent to Acquire Proscia, Advancing AI-Enabled Digital Pathology and Scientific Intelligence
Is Agilent Technologies (A) Outperforming Other Medical Stocks This Year?
Dividend Champion, Contender, And Challenger Highlights: Week October 4
Agilent Introduces the NovoStation Sample Preparation System for Automated Flow Cytometry Workflows
A DCF Analysis: Intrinsic Value $120 vs Price $175
Agilent Technologies (NYSE:A) Hits New 52-Week High – What’s Next?
Agilent Introduces Gen5 AI Cell Identification Module for BioTek Automated Cell Imagers
Agilent Technologies, Inc. (NYSE:A) Stock Now Rated “Moderate Buy” by Sell-Side Brokerages
Agilent (A) Up 9.6% Since Last Earnings Report: Can It Continue?
Agilent Technologies, Inc. (A) Presents at U.S. All Stars Conference Transcript
Agilent Technologies Sees Growth From China, Replacement Cycles and Lab Automation
Agilent Launches TapeStationDx Systems for Clinical NGS Sample Quality Control
Bank of America Corp DE Makes New Investment in Agilent Technologies, Inc. $A
CORRECTING and REPLACING Agilent Announces Cash Dividend of 25.5 Cents per Share